The agency said the pathway aims to improve access to breakthrough medical devices. The MDMA said it is disappointed by the ruling.
“We appreciate CMS’ efforts to improve the Coverage with Evidence Development pathway, but limiting eligibility to only five technologies a year means it is unlikely to meaningfully improve access or address disincentives to medical innovation caused by the current Medicare coverage process,” the organization said in a statement.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
